

0300

PATENT
Docket No. 532732000101

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Box Sequence, Assistant Commissioner for Patents, Washington, D.C. 20231, on July 9, 2002

U. Britva
Irina Britva

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Jing MA and Yajun GUO

Serial No.: 09/915,746

Filing Date: July 26, 2001

For: METHOD AND COMPOSITION FOR
DIAGNOSIS OF MELANOCYTIC
LESIONS

Examiner: To be Assigned

Group Art Unit: 1642

**COPY OF PAPERS
ORIGINALLY FILED**

TRANSMITTAL

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Attached hereto for filing are the following:

1. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
2. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
3. Return postcard

In the unlikely event that the Patent Office determines that extensions and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or fees due to our Deposit Account No. 03-1952 under Order No. 532732000101. The Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.


Respectfully submitted,

Dated: July 9, 2002

By: 

Peng Chen
Registration No. 43,543

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5117
Facsimile: (858) 720-5125



PATENT
Docket No. 532732000101

#10

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Box Sequence, Assistant Commissioner for Patents, Washington, D.C. 20231, on July 9, 2002

Irina Brava
Irina Brava

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Jing MA and Yajun GUO

Serial No.: 09/915,746

Filing Date: July 26, 2001

For: METHOD AND COMPOSITION FOR
DIAGNOSIS OF MELANOCYTIC
LESIONS

Examiner: To be Assigned

Group Art Unit: 1642

COPY OF PAPERS
ORIGINALLY FILED

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated May 9, 2002, for which a response is set to expire July 9, 2002. Accordingly, this response is timely filed.

Please enter the following remarks.

REMARKS


It is believed that a Sequence Listing is not required for the above-mentioned patent application as there are no nucleotide and/or amino acid sequence disclosures in the Specification and the Drawings to be included in a Sequence Listing. Applicants respectfully request that the U.S. Patent Office identify any sequences necessitating such a Sequence Listing if it disagrees.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. **532732000101**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.


Respectfully submitted,

Dated: July 9, 2002

By: _____


Peng Chen
Registration No. 43,543

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5117
Facsimile: (858) 720-5125



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/915,746	07/26/2001	Yajun Guo	67146403-1015

CONFIRMATION NO. 1834

FORMALITIES LETTER



OC000000008075638

John G. Flaim/Pamela Wong
BAKER & MCKENZIE
Suite 2300
2001 Ross Avenue
Dallas, TX 75201

COPY OF PAPERS
ORIGINALLY FILED

Date Mailed: 05/09/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- o This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.